November 6, 2026

To whom it may concern


Company Name: Innovacell Inc.
Representative: Representative Director and Co-CEO
Colin Novick
Representative: Representative Director and Co-CEO
Jason Sieger
(Securities Code: 504A, Growth Market of the Tokyo Stock Exchange)
Point of Contact: Director and CFO Yasushi Hosono
(https://innovacell.com/contact/?lang=en)


# Notice Regarding the Publication of a Co-CEOs Interview with "*Growthstock Pulse*," an Online Media Outlet Specializing in Startups

We are pleased to announce that an interview with our Co-CEOs, Colin Novick and Jason Sieger, has been published on "*Growthstock Pulse*," an online media outlet that covers the challenges faced by startups in Japan and Asia.

In this two-part article, our two Co-CEOs share the story of our 25-year journey, from our origins as a cell therapy venture spun out of the Medical University of Innsbruck in Austria, through the development of cell therapy technologies and products targeting fecal and urinary incontinence, to the establishment of a new parent company in Japan via a triangular merger and our subsequent listing on the Japanese stock market.

The full article is available free of charge in both Japanese and English. We invite you to read it and learn more about the journey behind our company.

Full articles:

(Part 1) How Innovacell Survived 25 Years in Diseases Nobody Talks About - Growthstock Pulse

(Part 2) Why Innovacell Became a Japanese Company and Chose a Tokyo Listing - Growthstock Pulse

A summary of this article is also available on the "Executive Interview" page in the Cross-Border IPO section on the Tokyo Stock Exchange (TSE) website under the "TSE Asia Startup Hub," a program led by TSE:

Innovacell Inc. | Executive Interview | Cross-Border IPO | Japan Exchange Group (English)

**■ About Innovacell Inc. (https://innovacell.com/?lang=en)**

Innovacell Inc. was established in Japan in 2021 as the parent company of a regenerative medicine company spun off from the Medical University of Innsbruck in Austria, and was listed on the Tokyo Stock Exchange Growth Market in February 2026 (Securities Code: 504A).

Our Group aims to improve people's health and quality of life through the commercialization of cell therapy and regenerative medicine, and we are currently engaged in the research, development, and commercialization of regenerative medicine products for the treatment of incontinence (urge fecal incontinence, passive fecal incontinence, and stress urinary incontinence). To date, our Group has completed multiple clinical trials in Europe (including late-stage Phase II trials) for two pipeline programs: ICEF15 (indication: urge fecal incontinence) and ICES13 (indication: stress urinary incontinence). For more details, please visit our website or our YouTube channel.

End